Zn(II)-curc targets p53 in thyroid cancer cells
TP53 mutation is a common event in many cancers, including thyroid carcinoma. Defective p53 activity promotes cancer resistance to therapies and a more malignant phenotype, acquiring oncogenic functions. Rescuing the function of mutant p53 (mutp53) protein is an attractive anticancer therapeutic str...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583539/ |